This series of activities is designed for neurologists and primary care physicians (including family practice, internists, and general practitioners), as well as nurses and pharmacists, who manage and treat patients with multiple sclerosis.
The goal of this CME/CE activity is to examine current and emerging strategies for diagnosing, treating, and managing patients with multiple sclerosis.
Learning Objective (s)
- Assess the importance of early treatment intervention on disease progression and disability to ensure improved patient outcomes.
- Assess and differentiate current and emerging small molecule MS therapies and how to integrate them into treatment regimens that optimize patient outcomes by slowing/stabilizing disease progression.
- Utilize methodologies (eg, MRI)/tools to tailor treatment and personalize MS therapy to improve overall patient outcomes.
- Integrate new strategies for optimizing immunosuppressive and immunomodulatory treatments, including induction therapy with an immunosuppressant followed by maintenance therapy with an immunomodulatory therapy, to control disease progression while minimizing side effects.
- Utilize interventions that manage patient symptoms (walking impairment/spasticity, neurogenic bladder dysfunction) associated with MS in order to improve overall patient QOL.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Projects In Knowledge® designates this enduring material for a maximum of 5.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Specific credit information can be found on each activity's web page.
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that all those who have control of content comply with the Standards for Commercial Support. Faculty, planners, PIK editorial scientific team, reviewers, and medical writers are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed during the presentations.
James D. Bowen, MD received financial support for research activities from Acorda Therapeutics, Artielle, BioMS Medical, Novartis and UCB Inc. and has been a consultant for Bayer Healthcare, Biogen/Idec, EMD Serono Inc., and Teva Neuroscience.
Patricia K. Coyle, MD has received consulting fees from Acorda Therapeutics, Inc. Biogen IDEC, EMD-Serono, Genetech, sanofi- aventis, and Teva; contracted for Actelion Pharmaceuticals US, Inc., EMD-Serono, and Novartis Pharmaceuticals Corporation.
Anne H. Cross, MD has received salary/honoraria from Bayer Healthcare Pharmaceuticals Inc., Biogen Idec, Genentech, Inc, and Teva Neuroscience; has received consulting fees from Bayer Healthcare Pharmaceuticals Inc., Biogen Idec, Eli Lilly and Company, Hoffmann-LaRoche Ltd, and Teva Neuroscience; has conducted contracted research for Acorda Therapeutics, Inc. and sanofi-aventis; and has ownership/interest in Affymetrix, Inc.
Andrew D. Goodman, MD is a consultant for Acorda Therapeutics Inc., Avanir Pharmaceuticals Inc., Biogen IDEC, EMD-Serono, Genzyme Corporation, Novartis Pharmaceuticals Corporation, sanofi-aventis, Teva Neuroscience, and Vaccinex, Inc; and has performed contracted research for Acorda Therapeutics Inc., Biogen IDEC, EMD-Serono, Genzyme Corporation, Novartis Pharmaceuticals Corporation, Ono Pharmaceutical Co, Ltd, Takeda Pharmaceuticals U.S.A., Inc., and Teva Neuroscience.
Clyde E. Markowitz, MD has received honoraria from Bayer, Biogen Idec, and Teva Neuroscience; is a consultant for Bayer, Genentech Inc, Biogen Idec, BioMS Medical, Eli Lilly and Company, EMD Serono, Novartis Pharmaceuticals Corporation and Teva Neuroscience.
Victor Nitti, MD has received consulting fees from Allergan, American Medical Systems, Astellas, Coloplast, Ethicon, Medtronic, Pfizer, Serenity and Uroplasty; and has conducted contracted research for Allergan and Astellas.
Peer Reviewer has disclosed no relevant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no relevant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no relevant relationships to disclose.
Projects In Knowledge's staff members have no relevant relationships to disclose.
These activities may contain discussions of unlabeled/unapproved uses of drugs or devices. Specific product disclosure will be forthcoming in each activity.
The opinions expressed in these activities are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.